LON:ARIXArix Bioscience Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arix Bioscience PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 95.50 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range 88.13Now: GBX 95.50▼ 9850-Day Range 60MA: GBX 83.29▼ 95.5052-Week Range 57Now: GBX 95.50▼ 149Volume100,462 shsAverage Volume65,433 shsMarket Capitalization£129.45 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlines Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is based in London, United Kingdom with an additional office in New York, New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Arix Bioscience. Previous Next 2.3 Community Rank Outperform VotesArix Bioscience has received 77 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArix Bioscience has received 92 “underperform” votes. (Add your “underperform” vote.)Community SentimentArix Bioscience has received 54.44% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arix Bioscience and other stocks. Vote “Outperform” if you believe ARIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArix Bioscience does not currently pay a dividend.Dividend GrowthArix Bioscience does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arix Bioscience insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Arix Bioscience is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arix Bioscience is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArix Bioscience has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.59 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ARIX Previous Symbol CUSIPN/A CIKN/A Webarixbioscience.com Phone+44-20-72901050Debt Debt-to-Equity Ratio0.47 Current Ratio8.16 Quick Ratio8.11Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£-58,136,000.00 Price / Sales-2.23 Cash FlowGBX 41.90 per share Price / Cash Flow2.28 Book ValueGBX 154.90 per share Price / Book0.62Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares135,552,000Market Cap£129.45 million Next Earnings DateN/A OptionableNot Optionable LSE:ARIX Rates by TradingView Receive ARIX News and Ratings via Email Sign-up to receive the latest news and ratings for ARIX and its competitors with MarketBeat's FREE daily newsletter. Arix Bioscience (LON:ARIX) Frequently Asked Questions How has Arix Bioscience's stock been impacted by COVID-19 (Coronavirus)? Arix Bioscience's stock was trading at GBX 77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARIX stock has increased by 24.0% and is now trading at GBX 95.50. View which stocks have been most impacted by Coronavirus. Has Arix Bioscience been receiving favorable news coverage? Media stories about ARIX stock have trended somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arix Bioscience earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutArix Bioscience. Who are some of Arix Bioscience's key competitors? Some companies that are related to Arix Bioscience include Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV), Emblem (EMC), Pfenex (PFNX), Exicure (XCUR) and Fennec Pharmaceuticals (FRX). View all competitors. What other stocks do shareholders of Arix Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arix Bioscience investors own include Adamas Pharmaceuticals (ADMS), ADMA Biologics (ADMA), AcelRx Pharmaceuticals (ACRX), Aclaris Therapeutics (ACRS), AC Immune (ACIU), Acer Therapeutics (ACER), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), ABIOMED (ABMD) and Abeona Therapeutics (ABEO). Who are Arix Bioscience's key executives? Arix Bioscience's management team includes the following people: Dr. Joseph Anderson, CEO & Co-Founder (Age 60)Mr. James Hedley Rawlingson, Chief Financial Officer (Age 51)Sir Christopher Thomas Evans, Consultant (Age 62)Mr. Robert Lyne, COO, Gen. Counsel & Company Sec.Ms. Charlotte Parry, Head of Investor Relations What is Arix Bioscience's stock symbol? Arix Bioscience trades on the London Stock Exchange (LON) under the ticker symbol "ARIX." How do I buy shares of Arix Bioscience? Shares of ARIX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Arix Bioscience's stock price today? One share of ARIX stock can currently be purchased for approximately GBX 95.50. How big of a company is Arix Bioscience? Arix Bioscience has a market capitalization of £129.45 million and generates £-58,136,000.00 in revenue each year. Arix Bioscience employs 14 workers across the globe. What is Arix Bioscience's official website? The official website for Arix Bioscience is arixbioscience.com. How can I contact Arix Bioscience? Arix Bioscience's mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The company can be reached via phone at +44-20-72901050. This page was last updated on 5/30/2020 by MarketBeat.com Staff
